KEAP1 and cancer: Many cancers express gain-of-function Nrf-2 mutants or loss-of-function Keap1 mutations that lead to constitutive Nrf-2 activation [36, 37], which contributes to the resistance against oxidative stress, such as chemotherapeutic drugs and ionizing radiation [38].